TRANSCATHETER AORTIC VALVE REPLACEMENT MARKET:TRENDS ANALYSIS AND FORECASTS UP TO 2022
Transcatheter Aortic Valve Replacement (TAVR),
also referred as Transcatheter Aortic Valve Implanta-
tion (TAVI) is a minimally invasive surgical procedure
repairs the valve without removing the old, damaged
valve. Instead, it wedges a replacement valve into the
aortic valves place. Normally valve replacement
method requires an open heart procedure with a ster-
notomy, in which the chest is surgically separated for
the treatment. Whereas, the TAVR procedures can
be done through very small openings that leave all
the chest bones in place. There are two methods
available for TAVR surgical procedure, which in-
cludes:
Entering through the femoral artery (large artery
in the groin), called the transfemoral approach,
which does not require a surgical incision in the
chest.
or
A minimally invasive surgical approach with a
small incision in the chest and entering through a
large artery in the chest or through the tip of the
left ventricle (the apex), which is known as the
transapical approach.
Recent clinical trials on TAVR devices proved that
these devices are non-inferior, and possibly superior,
to Surgical Aortic Valve Replacement (SAVR) within
the intermediate risk patient population. These trials
were also noteworthy for the low complication rates
observed in the TAVR groups. As TVARs application
moves from inoperable and high risk patients to pa-
tients who have moderate or lower risk for open heart
surgery, the market will expand exponentially in the
coming years.
Some of the key driving factors attributing to the
growth of this market include increasing number of
patients with cardiovascular diseases such as hyper-
tension, heart failures and coronary artery diseases.
In addition, increasing adoption of minimally invasive
procedures over traditional surgical open heart proce-
dures, reduction in hospital stays, low risk of infec-
tion, minimal blood loss are further propelling the
market. According to World Health Organization
(WHO), it has been estimated that the number of
people suffering from cardiovascular diseases will
increase to 22.2 million by 2030. The market for
TAVR is expected to reach around USD 6.5 billion by
2022, growing at a CAGR of 21.3% during the fore-
cast period of 2016e to 2022f. However, there are
certain restraining factors which could hamper the
growth of this market, which includes, high costs as-
sociated with the LAVD implantation compared to
other therapies available for CVD diseases. A TAVR
device costs USD 30,000, which is six times the price
of the average surgical valve. In addition, for a hospi-
tal to be reimbursed for a TAVR procedure, the pa-
tient must be evaluated by a multidisciplinary team
that involves multiple cardiac surgeons and interven-
tional cardiologists. However, there are some cost
savings compared to surgery, such as shorter length
of stay in the hospital.
Geographically, North America is leading contributor
to the market and is expected to retain its position
during the forecast period. Nonetheless, the market
for Asia-Pacific region is expected to grow at a faster
rate owing to increasing prevalence of CVD diseases,
growing awareness about minimally invasive surgical
procedures among the population, improving
healthcare infrastructure, rise in healthcare spending,
and favorable government policies.
Companies profiled:
Edwards Lifesciences Corp.
Boston Scientific Corp.
Direct Flow medical, Inc.
Bracco SpA.
JenaValve Technology, Inc.
Medtronic plc
Meril Life Sciences Pvt. Ltd.
Jude Medical, Inc.
To purchase complete report on Transcatheter aortic valve replacement (TAVR) Market visit:

URL: https://www.infiniumglobalresearch.com/reports/transcatheter-aortic-valve-replacement-
tavr-market

website : www.infiniumglobalresearch.com

Contact us:

Email sales@infiniumglobalresearch.com

Skypeid: infiniumglobalresearch